Table 1. Comparisons of patients’ characteristics and other variables between GA group and LA group in the entire cohort.
| Variables | Before PSM | After PSM | |||||
|---|---|---|---|---|---|---|---|
| GA Group, (n=244) | LA Group, (n=245) | P value | GA Group, (n=178) | LA Group, (n=178) | P value | ||
| Propensity score | 0.54 (0.15) | 0.46 (0.13) | 0 | 0.50 (0.12) | 0.50 (0.12) | 0.944 | |
| Sex | |||||||
| Male | 202 | 193 | 0.26 | 149 | 144 | 0.487 | |
| Female | 42 | 52 | 29 | 34 | |||
| Age | 57.8 (9.3) | 55.9 (10.2) | 0.035 | 56.12 (9.86) | 57.58 (9.40) | 0.155 | |
| ≤60 | 147 | 156 | 0.435 | 111 | 113 | 0.826 | |
| >60 | 97 | 89 | 67 | 65 | |||
| ASA score | |||||||
| II | 201 | 196 | 0.501 | 143 | 144 | 0.893 | |
| III | 43 | 49 | 35 | 34 | |||
| Hypertension (yes/no) | 62/182 | 56/189 | 0.509 | 38/140 | 40/138 | 0.798 | |
| Diabetes (yes/no) | 29/215 | 38/207 | 0.244 | 23/155 | 21/157 | 0.747 | |
| Cardiopathy† (yes/no) | 10/234 | 13/232 | 0.528 | 6/172 | 6/172 | 1 | |
| Tumor number | 1.2 (0.5) | 1.2 (0.4) | 0.464 | 1.21 (0.46) | 1.16 (0.40) | 0.271 | |
| Solitary | 201 | 207 | 0.53 | 144 | 151 | 0.325 | |
| Multiple | 43 | 38 | 34 | 27 | |||
| Cirrhosis (yes/no) | 197/47 | 188/57 | 0.279 | 141/37 | 139/39 | 0.796 | |
| HBV/HCV infection (yes/no) | 209/35 | 213/32 | 0.68 | 153/25 | 150/28 | 0.655 | |
| Adjuvant chemoradiotherapy‡ (yes/no) | 82/162 | 40/205 | 0 | 39/139 | 37/141 | 0.796 | |
| Child-Pugh stage | |||||||
| A | 219 | 225 | 0.426 | 158 | 161 | 0.602 | |
| B | 25 | 20 | 20 | 17 | |||
| Tumor size | 2.8 (1.1) | 2.5 (1.1) | 0.001 | 2.62 (1.16) | 2.69 (1.06) | 0.509 | |
| <3 cm | 134 | 164 | 0.006 | 104 | 108 | 0.666 | |
| ≥3 cm | 110 | 81 | 74 | 70 | |||
| TNM stage | |||||||
| I | 197 | 198 | 0.982 | 140 | 148 | 0.281 | |
| II | 47 | 47 | 38 | 30 | |||
| AFP* | 16.9 [4.6, 168.3] | 15.7 [3.7, 167.1] | 0.444 | 17.0 [5.3, 157.5] | 13.8 [3.5, 129.4] | 0.18 | |
| <400 ng/mL | 204 | 211 | 0.438 | 153 | 151 | 0.764 | |
| ≥400 ng/mL | 40 | 34 | 25 | 27 | |||
| TBIL | 16.6 [12.0, 24.0] | 14.6 [10.9, 21.9] | 0.02 | 16.6 [11.8, 24.1] | 14.4 [10.5, 21.3] | 0.026 | |
| <34 mmol/L | 219 | 224 | 0.526 | 161 | 159 | 0.725 | |
| ≥34 mmol/L | 25 | 21 | 17 | 19 | |||
| ALB | 40.5 (6.1) | 40.7 (4.9) | 0.658 | 41.0 (5.8) | 40.1 (5.0) | 0.104 | |
| ≤35 g/L | 48 | 31 | 0.035 | 30 | 29 | 0.887 | |
| >35 g/L | 196 | 214 | 148 | 149 | |||
| ALT | 33.2 [23.0, 49.5] | 33.0 [21.2, 53.5] | 0.715 | 33.0 [22.6, 47.2] | 32.0 [21.0, 50.3] | 0.598 | |
| <40 U/L | 152 | 146 | 0.54 | 112 | 116 | 0.659 | |
| ≥40 U/L | 92 | 99 | 66 | 62 | |||
| AST | 34.7 [26.3, 61.8] | 33.0 [22.1, 56.5] | 0.162 | 34.4 [25.0, 58.0] | 33.0 [22.4, 54.3] | 0.383 | |
| <40 U/L | 143 | 145 | 0.897 | 106 | 106 | 1 | |
| ≥40 U/L | 101 | 100 | 72 | 72 | |||
| Postoperative complications§ | 19 | 20 | 0.878 | 12 | 16 | 0.431 | |
| Fever | 8 | 13 | 0.269 | 3 | 11 | 0.053 | |
| Pain | 10 | 7 | 0.454 | 7 | 5 | 0.557 | |
| Seroperitoneum | 2 | 1 | 0.623 | 2 | 0 | 0.499 | |
| Infection | 1 | 0 | 0.499 | 1 | 0 | 1 | |
Variables are shown as “mean (SD)” or “median [25% quartile, 75% quartile]”. †, cardiopathy illnesses include coronary heart disease, heart failure (NYHA I–II), arrhythmia, myocardiopathy and valvulopathy; ‡, adjuvant chemoradiotherapy includes transcatheter arterial chemoembolization (TACE) and radioactive seed implantation. Adjuvant chemoradiotherapy is defined as patients received TACE or radioactive seed implantation simultaneously with or after TA surgery; §, the number of patients who had postoperative complications is sometimes smaller than the summary of patients’ number with individual complications because some patients had more than one complication. ASA, American Society of Anesthesiologists; HBV, hepatitis B virus; HCV, hepatitis C virus; TNM, Clinicopathological stage; AFP, alpha-fetoprotein; TBIL, total bilirubin; ALB, serum albumin; ALT, Alanine transaminase; AST, aspartate aminotransferase; SD, standard deviation; GA, general anesthesia; LA, local anesthesia.